: Merck swings to loss as it books charge on $10.8 billion acquisition of Prometheus Biosciences
Merck's earnings were also hit by lower sales of its COVID antiviral Lagevrio.
Merck's earnings were also hit by lower sales of its COVID antiviral Lagevrio.